Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed NNRTI RAMs on virological response to an RPV- or efavirenz (EFV)-containing regimen were analysed.
Methods
ECHO and THRIVE were global, Phase III, double-blind, double-dummy, randomized trials in antiretroviral treatment-naive, HIV-1-infected adults to determine whether RPV 25 mg once daily had non-inferior efficacy versus EFV 600 mg once daily, both given with tenofovir/ emtricitabine (ECHO) or tenofovir/emtricitabine, zidovudine/lamivudine or abacavir/lamivudine (THRIVE). The prevalence of 49 NNRTI RAMs, including the predefined list of 39 NNRTI RAMs used to exclude patients with potential resistance to RPV or EFV, was investigated at screening by population sequencing (including mixtures) using the virco®TYPE HIV-1 genotyping assay.
Results
Of the 1,796 screened patients in whom genotypic resistance results were available, 372 (21%) had NNRTI RAMs. Of 527 screening failures, 148 (28%) were due to the presence of NNRTI RAMs. The presence of allowed NNRTI RAMs was associated with comparable response rates to the overall population (RPV 84.3% versus EFV 82.3%, intent-to-treat time-to-loss-of-virological-response): V90I (82.4% and 100% for RPV and EFV, respectively), V106I (85.7% and 93.3%), V179I (87.7% and 94.0%) and V189I (100.0% and 88.9%).
Conclusions
Analysis of the ECHO and THRIVE screened population suggests that transmitted NNRTI resistance is prevalent in treatment-naive patients but prevalence of the 15 RPV RAMs remains low. The four allowed NNRTI RAMs present at baseline did not affect RPV response at week 48. Virus Drug Resistance and Curative Strategies (Los Cabos, Mexico, 7–11 June 2011, abstract 41).
CohenC.J., Andrade-VillanuevaJ., ClotetB.Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet2011; 378: 229–237.
3.
MolinaJ.M., CahnP., GrinsztejnB.Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a Phase 3 randomised double-blind active-controlled trial. Lancet2011; 378: 238–246.
4.
CohenC.J., MolinaJ.M., CassettiI.Pooled week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults.6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 17–20 July 2011, Rome, Italy. Abstract TULBPE032.
5.
DelaugerreC., RohbanR., SimonA.Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol2001; 65: 445–448.
6.
JohnsonV.A., Brun-VezinetF., ClotetB.Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med2006; 14: 125–130.
7.
TambuyzerL., AzijnH., RimskyL.T.Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther2009; 14: 103–109.
8.
VingerhoetsJ., TambuyzerL., AzijnH.Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS2010; 24: 503–514.
9.
JohnsonV.A., Brun-VezinetF., ClotetB.Update of the drug resistance mutations in HIV-1. Top HIV Med2008; 16: 138–145.
10.
PozniakA.L., Morales-RamirezJ., KatabiraE.Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a Phase IIb randomized trial. AIDS2010; 24: 55–65.
11.
DeanJ., Ta ThiT.H., DunfordL.Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a multicenter study. AIDS Res Hum Retroviruses2011; 27: 797–801.
12.
MetznerK.J., GiulieriS.G., KnoepfelS.A.Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis2009; 48: 239–247.
13.
Van LaethemK., De MunterP., SchrootenY.No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol2007; 39: 43–47.
14.
Stanford University.Stanford University HIV Drug Resistance Database. (Accessed 3 February 2012.) Available from http://hivdb.stanford.edu/.
15.
MackieN., GarveyL., GerettiA.M.Predicting NNRTI resistance: do polymorphisms matter?18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 595.
